Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y

Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu

Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj

Sunday: ACR 2022 Daily Recap https://t.co/9naWAYwJIV

#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP

Lifetime career achievement ✔️ - first author of a paper in ACR year in review #ACR22 https://t.co/M5GrOcWY5X

$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v

Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7

@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22 @jhrheumatology @JHRheumFellows https://t.co/aSRHiJoIkE